Prognostic Value of MTV, SUVmax and the T/N Ratio of PET/CT in Patients with Glioma: A Systematic Review and Meta-Analysis

Overview

Journal J Cancer

Specialty Oncology

Date 2019 Jun 18

PMID 31205526

Citations 10

Authors

Qing Zhang

Xian Gao

Guohua Wei

Cheng Qiu

Hongyi Qu

Xin Zhou

Affiliations

Soon will be listed here.

Abstract

In the past decade, positron emission tomography/computed tomography (PET/CT) has become an important imaging tool for clinical assessment of tumor patients. Our meta-analysis aimed to compare the predictive value of PET/CT parameters regard to overall survival (OS) and progression-free survival (PFS) outcomes in glioma. Relevant articles were systematically searched in PMC, PubMed, EMBASE and WEB of science. Studies involving the prognostic roles of PET/CT parameters with OS and PFS in glioma patients were evaluated. The impact of metabolic tumor volume (MTV), maximal standard uptake value (SUVmax), and the ratio of uptake in tumor to normal (T/N ratio) on survival was measured by calculating combined hazard ratios (HRs) and 95% confidence intervals (CIs). A total of 32 articles with 1715 patients were included. The combined HRs of higher MTV, higher SUVmax and higher T/N ratio for OS were 1.14 (95% CI: 0.98-1.32, P heterogeneity<0.001), 1.69 (95% CI: 1.18-2.41, P heterogeneity<0.001) and 1.68 (95% CI: 1.40-2.01, P heterogeneity< 0.001), respectively. Regarding PFS, the combined HRs were 1.04 (95% CI: 0.97-1.11, P heterogeneity=0.002) with higher MTV, 1.45 (95% CI: 1.11-1.90, P heterogeneity<0.001) with higher SUVmax and 2.07 (95% CI: 1.45-2.95, P heterogeneity<0.001) with higher T/N ratio. Results remained similar in the sub-group analyses. PET/CT parameters T/N ratio may be a significant prognostic factor in patients with glioma. Evidence of SUVmax and MTV needed more large-scale studies performed to validate. PET/CT scan could be a promising technique to provide prognostic information for these patients.

Citing Articles

Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value.

Bela Andela S, Amthauer H, Furth C, Rogasch J, Beck M, Mehrhof F Radiat Oncol. 2024; 19(1):97.

PMID: 39080696 PMC: 11288109. DOI: 10.1186/s13014-024-02483-w.

Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma.

Prexler C, Knape M, Erlewein-Schweizer J, Roll W, Specht K, Woertler K Cancers (Basel). 2022; 14(23).

PMID: 36497479 PMC: 9735504. DOI: 10.3390/cancers14235999.

Clinical Perspectives for F-FDG PET Imaging in Pediatric Oncology: Μetabolic Tumor Volume and Radiomics.

Lyra V, Chatziioannou S, Kallergi M Metabolites. 2022; 12(3).

PMID: 35323660 PMC: 8956064. DOI: 10.3390/metabo12030217.

A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3).

Laffi A, Colandrea M, Buonsanti G, Frassoni S, Bagnardi V, Spada F Diagnostics (Basel). 2021; 11(12).

PMID: 34943637 PMC: 8700454. DOI: 10.3390/diagnostics11122401.

Dynamic C-Methionine PET-CT: Prognostic Factors for Disease Progression and Survival in Patients with Suspected Glioma Recurrence.

Mattoli M, Trevisi G, Scolozzi V, Capotosti A, Cocciolillo F, Marini I Cancers (Basel). 2021; 13(19).

PMID: 34638262 PMC: 8508090. DOI: 10.3390/cancers13194777.

References

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

Stupp R, Dietrich P, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P . Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002; 20(5):1375-82. DOI: 10.1200/JCO.2002.20.5.1375. View

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

Chen W, Silverman D, Delaloye S, Czernin J, Kamdar N, Pope W . 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006; 47(6):904-11. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Toyohara J, Okada M, Toramatsu C, Suzuki K, Irie T . Feasibility studies of 4'-[methyl-(11)C]thiothymidine as a tumor proliferation imaging agent in mice. Nucl Med Biol. 2007; 35(1):67-74. DOI: 10.1016/j.nucmedbio.2007.10.001. View

Swanson K, Chakraborty G, Wang C, Rockne R, Harpold H, Muzi M . Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2008; 50(1):36-44. PMC: 4154624. DOI: 10.2967/jnumed.108.055467. View

de Vries N, Beijnen J, van Tellingen O . High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev. 2009; 35(8):714-23. DOI: 10.1016/j.ctrv.2009.08.011. View

Porter K, McCarthy B, Freels S, Kim Y, Davis F . Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010; 12(6):520-7. PMC: 2940648. DOI: 10.1093/neuonc/nop066. View

10.

Kinahan P, Fletcher J . Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010; 31(6):496-505. PMC: 3026294. DOI: 10.1053/j.sult.2010.10.001. View

11.

Fougere C, Suchorska B, Bartenstein P, Kreth F, Tonn J . Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011; 13(8):806-19. PMC: 3145468. DOI: 10.1093/neuonc/nor054. View

12.

Colavolpe C, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Figarella-Branger D . Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. J Neurooncol. 2011; 107(3):527-35. DOI: 10.1007/s11060-011-0771-6. View

13.

Zhu W, Xing L, Yue J, Sun X, Zhao H, Yu J . Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis. Br J Radiol. 2012; 85(1017):e694-701. PMC: 3487087. DOI: 10.1259/bjr/29946900. View

14.

Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C . FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol. 2012; 14(5):649-57. PMC: 3337300. DOI: 10.1093/neuonc/nos012. View

15.

James M, Gambhir S . A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012; 92(2):897-965. DOI: 10.1152/physrev.00049.2010. View

16.

Treglia G, Giovannini E, Di Franco D, Calcagni M, Rufini V, Picchio M . The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med. 2012; 26(6):451-61. DOI: 10.1007/s12149-012-0602-7. View

17.

Alkonyi B, Barger G, Mittal S, Muzik O, Chugani D, Bahl G . Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of α-11C-methyl-L-tryptophan PET. J Nucl Med. 2012; 53(7):1058-64. PMC: 3777234. DOI: 10.2967/jnumed.111.097881. View

18.

Anton K, Baehring J, Mayer T . Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am. 2012; 26(4):825-53. DOI: 10.1016/j.hoc.2012.04.006. View

19.

Idema A, Hoffmann A, Boogaarts H, Troost E, Wesseling P, Heerschap A . 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med. 2012; 53(12):1904-10. DOI: 10.2967/jnumed.112.105544. View

20.

Tsougos I, Svolos P, Kousi E, Fountas K, Theodorou K, Fezoulidis I . Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Cancer Imaging. 2012; 12:423-36. PMC: 3494384. DOI: 10.1102/1470-7330.2012.0038. View